Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
Effect of G17DT in Patients With Stage II/III Colorectal Cancer
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- Cancer Advances Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02518373
The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease
- Conditions
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Torax Medical Incorporated
- Target Recruit Count
- 152
- Registration Number
- NCT02505945
- Locations
- 🇺🇸
Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, United States
🇺🇸SurgOne Foregut Institute, Englewood, Colorado, United States
🇺🇸UCSD, San Diego, California, United States
Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-06-21
- Lead Sponsor
- Menarini International Operations Luxembourg SA
- Target Recruit Count
- 196
- Registration Number
- NCT02500641
- Locations
- 🇵🇱
Specjalistyczna Praktyka Lekarska Piotr Kubalski, Grudziądz, Poland
🇵🇱Oddział Kardiologiczny, WSS im. W. Biegańskiego w Łodzi, Łódź, Poland
🇷🇴S.C. Cardiomed S.R.L., Craiova, Romania
A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Target Recruit Count
- 14
- Registration Number
- NCT02492776
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 18
- Registration Number
- NCT02473627
Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Stephen Harbarth
- Target Recruit Count
- 39
- Registration Number
- NCT02472600
- Locations
- 🇫🇷
Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Clichy, France
🇳🇱Universitair Medisch Centrum Utrecht,, Utrecht, Netherlands
🇨🇭Geneva University Hospitals, Geneva, Switzerland
Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 120
- Registration Number
- NCT02422706
- Locations
- 🇪🇬
Tanta university hospital, Cairo, Egypt
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02397382
A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 34
- Registration Number
- NCT02365558
- Locations
- 🇺🇸
Covance Madison, Madison, Wisconsin, United States
Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT02345304
- Locations
- 🇩🇪
1344.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.